Preparation and characterization of monensin loaded PLGA nanoparticles: In vitro anti-malarial activity against Plasmodium falciparum

Journal of Biomedical Nanotechnology

Volumn 8, Issue 1, 2012, Pages 172-181

  Surolia, Ranu ^a   Pachauri, Manendra ^a   Ghosh, Prahlad Chandra ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Antimalarial efficacy; In vitro release; Malaria; Monensin; PLGA molecular weight; PLGA nanoparticles

Indexed keywords

ANTIMALARIAL EFFICACY; IN-VITRO; MALARIA; MONENSIN; PLGA NANOPARTICLES;

ATOMIC FORCE MICROSCOPY; DIFFERENTIAL SCANNING CALORIMETRY; DYNAMIC LIGHT SCATTERING; EMULSIFICATION; INFRARED SPECTROSCOPY; MOLECULAR WEIGHT; NANOPARTICLES;

IONOPHORES;

MONENSIN; NANOPARTICLE; POLYGLACTIN; POLYLACTIC CO GLYCOLIC ACID NANOPARTICLE; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DETERMINATION; DRUG RELEASE; DYNAMIC LIGHT SCATTERING; EMULSION; EVAPORATION; GROWTH INHIBITION; IN VITRO STUDY; INFRARED SPECTROSCOPY; LIGHT SCATTERING; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; PLASMODIUM FALCIPARUM;

ANTIMALARIALS; CALORIMETRY, DIFFERENTIAL SCANNING; CELLS, CULTURED; EMULSIONS; ERYTHROCYTES; HEMOLYSIS; HUMANS; LACTIC ACID; MOLECULAR WEIGHT; MONENSIN; NANOPARTICLES; PARTICLE SIZE; PLASMODIUM FALCIPARUM; POLYGLYCOLIC ACID; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84861472706     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2012.1366     Document Type: Article

References (49)

1. W. H. O. WHO. Malaria, http://www.who.int/features/factfiles/ malaria/en/index.html.
2. M. N. Huong, Resistance of Plasmodium falciparum to antimalarial drugs in a highly endemic area of southern Viet Nam: A study in vivo and in vitro. Transactions of the Royal Society of Tropical Medicine and Hygiene 95, 325 (2001).
3. H. Yang, Changes in susceptibility of plasmodium falciparum to artesunate in vitro in yunnan province, China. Transactions of the Royal Society of Tropical Medicine and Hygiene 97, 226 (2003).
4. H. Noedl, Evidence of artemisinin-resistant malaria in western Cambodia. Journal of Medicine 359, 2619 (2008).
5. H. Noedl, D. Duong, and W. Satimai, Artemisinin-resistant malaria in Asia. New England Journal of Medicine 361, 540 (2009).
6. P. Lim, Decreased in vitro susceptibility of plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007. Antimicrobial Agents and Chemotherapy 54, 2135 (2010).
7. A. A. Date, Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticle. Advanced Drug Delivery Reviews 59, 505 (2007).
8. H. H. Mollenhauer, D. J. Morre, and L. D. Rowe, Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicity. Biochim Biophys Acta 1031, 225 (1990).
9. E. G. Schildknecht, D. Siegel, and R. W. Richle, Antiparasitic activity of natural and semisynthetic monensin urethanes. Chemotherapy 29, 145 (1983).
10. M. Rochdi, A. M. Delort, J. Guyot, M. Sancelme, S. Gibot, J. G. Gourcy, G. Dauphin, C. Gumila, H. Vial, and G. Jeminet, Ionophore properties of monensin derivatives studied on human erythrocytes by 23Na NMR and K+ and H+ potentiometry: Relationship with antimicrobial and antimalarial activities. J. Med. Chem. 39, 588 (1996).
11. C. Gumila, M. L. Ancelin, A. M. Delort, G. Jeminet, and H. J. Vial, Characterization of the potent in vitro and in vivo antimalarial activities of ionophore compounds. Antimicrob Agents Chemother 41, 523 (1997).
12. C. Gumila, M. L. Ancelin, G. Jeminet, A. M. Delort, G. Miquel, and H. J. Vial, Differential in vitro activities of ionophore compounds against Plasmodium falciparum and mammalian cells. Antimicrob Agents Chemother 40, 602 (1996).
13. N. Mahmoudi, R. Garcia-Domenech, J. Galvez, K. Farhati, J. F. Franetich, R. Sauerwein, L. Hannoun, F. Derouin, M. Danis, and D. Mazier, New active drugs against liver stages of Plasmodium predicted by molecular topology. Antimicrob Agents Chemother 52, 1215 (2008).
14. R. Leitao and A. Rodriguez, Inhibition of plasmodium sporozoites infection by targeting the host cell. Exp. Parasitol. 126, 273 (2010).
15. J. Shaikh, D. D. Ankola, V. Beniwal, D. Singh, and M. N. Kumar, Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci. 37, 223 (2009).
16. E. A. Leite, A. Grabe-Guimaraes, H. N. Guimaraes, G. L. Machado- Coelho, G. Barratt, and V. C. Mosqueira, Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devices. Life Sci. 80, 1327 (2007).
17. C. Fonseca, S. Simoes, and R. Gaspar, Paclitaxel-loaded PLGA nanoparticles: Preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control Release 83, 273 (2002).
18. S. E. Haas, C. C. Bettoni, L. K. de Oliveira, S. S. Guterres, and T. Dalla Costa, Nanoencapsulation increases quinine antimalarial efficacy against Plasmodium berghei in vivo. Int. J. Antimicrob Agents 34, 156 (2009).
19. J. K. Vasir and V. Labhasetwar, Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev. 59, 718 (2007).
20. M. L. Hans and A. M. Lowman, Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Sol. State Mater. Sci. 6, 319 (2002).
21. T. Gorner, R. Gref, D. Michenot, F. Sommer, M. N. Tran, and E. Dellacherie, Lidocaine-loaded biodegradable nanospheres. I. Optimization of the drug incorporation into the polymer matrix. J. Control Release 57,259-268, (1999).
22. M. Singh, T. Griffin, A. Salimi, R.G. Micetich, and H. Atwal, Potentiation of ricin A immunotoxin by monoclonal antibody targeted monensin containing small unilamellar vesicles. Cancer Lett 84, 15 (1994).
23. A. J. Ferdous, N. Y. Stembridge, and M. Singh, Role of monensin PLGA polymer nanoparticles and liposomes as potentiator of ricin A immunotoxins in vitro. J. Control Release 50, 71 (1998).
24. R. A. Jain, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21, 2475 (2000).
25. G. Mittal, D. K. Sahana, V. Bhardwaj, and M. N. Ravi Kumar, Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J. Control Release 119, 77 (2007).
26. M. R. Jenquin and J. W. McGinity, Characterization of acrylic resin matrix films and mechanisms of drug-polymer interactions. Int. J. Pharm. 101, 23 (1994).
27. V. M. Vasandani, S. Madan, and P. C. Ghosh, In vivo potentiation of ricin toxicity by monensin delivered through liposomes. Biochim. Biophys. Acta 1116, 315 (1992).
28. R. E. Desjardins, C. J. Canfield, J. D. Haynes, and J. D. Chulay, Quantitative assessment of antimalarial activity in vitro by a semi-automated microdilution technique. Antimicrob Agents Chemother 16, 710 (1979).
29. U. Bilati, E. Allemann, and E. Doelker, Poly(D,L-lactide-coglycolide) protein-loaded nanoparticles prepared by the double emulsion method-processing and formulation issues for enhanced entrapment efficiency. J. Microencapsul. 22, 205 (2005).
30. R. C. Mundargi, V. R. Babu, V. Rangaswamy, P. Patel, and T. M. Aminabhavi, Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J. Control Release 125, 193 (2008).
31. M. F. Zambaux, F. Bonneaux, R. Gref, P. Maincent, E. Dellacherie, M. J. Alonso, P. Labrude, and C. Vigneron, Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J. Control Release 50, 31 (1998).
32. R. M. Mainardes, M. P. D. Gremião, and R. C. Evangelista, Thermoanalytical study of praziquantel-loaded PLGA nanoparticles. Brazilian Journal of Pharmaceutical Sciences 42, 523 (2006).
33. A. Budhian, S. J. Siegel, and K. I. Winey, Haloperidol-loaded PLGA nanoparticles: Systematic study of particle size and drug content. Int. J. Pharm. 336, 367 (2007).
34. R. A. Graves, S. Pamujula, R. Moiseyev, T. Freeman, L. A. Bostanian, and T. K. Mandal, Effect of different ratios of high and low molecular weight PLGA blend on the characteristics of pentamidine microcapsules. Int. J. Pharm. 270, 251 (2004).
35. T. Govender, S. Stolnik, M. C. Garnett, L. Illum, and S. S. Davis, PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug. J. Control Release 57, 171 (1999).
36. H. J. Jeon, Y. I. Jeong, M. K. Jang, Y. H. Park, and J. W. Nah, Effect of solvent on the preparation of surfactant-free poly(DL-lactide-co- glycolide) nanoparticles and norfloxacin release characteristics. Int. J. Pharm. 207, 99 (2000).
37. V. Saxena, M. Sadoqi, and J. Shao, Indocyanine green-loaded biodegradable nanoparticles: Preparation, physicochemical characterization and in vitro release. Int. J. Pharm. 278, 293 (2004).
38. R. Jaliland and J. R. Nixon, Microencapsulation using poly(DL-lactic acid). III: Effect of polymer molecular weight on the release kinetics. J. Microencapsul 7, 357 (1990).
39. M. Liu, J. Dong, Y. Yang, X. Yang, and H. Xu, Characterization and release of triptolide-loaded poly (D,L-lactic acid) nanoparticles. Eur. Polym. J. 41, 375 (2005).
40. S. Gibot, G. Jeminet, J. Juillard, C. Gumila, M. L. Ancelin, H. Vial, and A. M. Delort, Cationomycin and monensin partition between serum proteins and erythrocyte membrane: Consequences for Na+ and K+ transport and antimalarial activities. Archives of Biochemistry and Biophysics 363, 361 (1999).
41. X. Huang and C. S. Brazel, On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Controlled Release 73, 121 (2001).
42. M. M. Gasper, D. Blanco, M. E. Cruz, and M. J. Alonso, Formulation of L-asparaginase-loaded poly(lactide-co-glycolide) nanoparticles: Influence of polymer properties on enzyme loading, activity and in vitro release. J. Control Release 52, 53 (1998).
43. E. Chambers and S. Mitragotri, Long circulating nanoparticles via adhesion on red blood cells: Mechanism and extended circulation, Exp. Biol. Med. (Maywood) 232, 958 (2007).
44. M. A. Soler, S. N. Bao, G. B. Alcantara, V. H. Tiburcio, G. R. Paludo, J. F. Santana, M. H. Guedes, E. C. Lima, Z. G. Lacava, and P. C. Morais, Interaction of erythrocytes with magnetic nanoparticles. J. Nanosci. Nanotechnol. 7, 1069 (2007).
45. B. M. Rothen-Rutishauser, S. Schurch, B. Haenni, N. Kapp, and P. Gehr, Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques. Environ. Sci. Technol. 40, 4353 (2006).
46. C. Caldeira, W. S. Neves, P. M. Cury, P. Serrano, M. A. Baptista, and E. A. Burdmann, Rhabdomyolysis, acute renal failure, and death after monensin ingestion. Am. J. Kidney Dis. 38, 1108 (2001).
47. A. C. Souza, F. S. Machado, M. R. Celes, G. Faria, L. B. Rocha, J. S. Silva, and M. A. Rossi, Mitochondrial damage as an early event of monensin-induced cell injury in cultured fibroblasts L929. J. Vet. Med. A Physiol. Pathol. Clin. Med. 52, 230 (2005).
48. D. Kim, H. El-Shall, D. Dennis, and T. Morey, Interaction of PLGA nanoparticles with human blood constituents. Colloids Surf B Biointerfaces 40, 83 (2005).
49. S. K. Bhavsar, M. Eberhard, D. Bobbala, and F. Lang, Monensin induced suicidal erythrocyte death. Cell Physiol. Biochem. 25, 745 (2010).